Search | Page 18 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

    ... to an Erythropoiesis Stimulating Agent (ESA) and/or Azacitidine (AZA) followed by a dose expansion part with an additional 30 ...

    Clinical Trial last updated 04/28/2016 - 4:14pm.

  2. Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

    ... agent (such as decitabine [Vidaza] and azacitidine [AZA]). ...

    Clinical Trial last updated 04/28/2016 - 12:21pm.

  3. Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)

    ... failure of treatment with a hypomethylating agent (HMA), azacitidine (AZA) or decitabine (DEC). ...

    Clinical Trial last updated 04/27/2016 - 12:49pm.

  4. Sexuality and Intimacy

    ... and joint pain. Hypomethlyating agents like azacitidine (Vidaza®) can cause nausea/vomiting, diarrhea, fatigue ...

    Page last updated 05/02/2016 - 10:09am.

  5. Sapacitibine shows promise for high-risk MDS patients

    ... drugs approved by the Food and Drug Administration are azacitidine (5-AZA, Vidaza®) and decitabine (Dacogen®). Both of ...

    Research Review last updated 05/02/2016 - 9:30am.

  6. Clinical Trials Report for April 2015

    ... to an Erythropoiesis Stimulating Agent (ESA) and/or Azacitidine (AZA) followed by a dose expansion part with an additional 30 ... Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) The goal of this ...

    Page last updated 03/30/2015 - 11:40am.

  7. Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation

    ... of 200 patients who were treated with Vidaza® ( azacitidine ), Dacogen® ( decitabine ), or both azacitidine and decitabine. The 76 patients in Cohort 2 underwent a stem ...

    Research Review last updated 05/02/2016 - 9:26am.

  8. Shyamala Navada, MD

    ... investigator of a clinical trial combining azacitidine and rigosertib in MDS patients that will soon be opening at ...

    Bio last updated 03/11/2016 - 1:41pm.

  9. Amer Zeidan, M.D.

    ... MDS who did not respond to the existing drugs (such as azacitidine and decitabine ) and are not candidates for stem cell ...

    Bio last updated 03/11/2016 - 1:41pm.

  10. Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.

    ... chemotherapy or lymphoma chemotherapy or azacitidine or decitabine or tyrosine kinase inhibitor. ... Receipt of at least one cycle of cytotoxic chemotherapy, azacitidine or decitabine. MDS patients must have < or = to 5% bone ...

    Clinical Trial last updated 04/29/2016 - 3:51pm.